Fresh analysis indicates that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional lifestyle programs.
Published data in a leading health publication demonstrates that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"People buying such medications need to be cognizant of the danger of rapid rebound weight gain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment mass within about a year and a half.
Comparing Approaches
The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of the injectable medications with other pills.
Scientists note that people who lose weight through dieting generally have a less rapid weight regain—around 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors propose the way of the jabs accounts for the accelerated regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Issue?
The NHS recommend the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, due to the high risk of weight regain, the therapy should be considered ongoing.
This view is echoed by pharmaceutical companies, who state that the findings "highlight the long-term character of obesity," similar to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the jabs report a sudden return of appetite.
"I experienced a switch activating and you're instantly extremely hungry," said one woman.
The struggle is exacerbated if patients have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Interest
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is greater among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, researchers emphasize that while these medications are powerful agents for weight loss, they are not a standalone fix and maintained weight loss relies on ongoing behavioural support.
